Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

Data ReadoutCRB-913Neutral

AI Analysis

Summary

Corbus Pharmaceuticals will host a conference call on September 14, 2026 to discuss topline data from the CANYON-1 clinical trial of CRB-913 for obesity treatment.

Clinical Trial Data

Importance:6/10

Sentiment:

0.00

clinical trialtopline dataobesityCRB-913CANYON-1

Related Companies

$CRBP

Read the original article

Published by GlobeNewswire Clinical Studies on September 11, 2026 8:01 PM

Read Original